AAAAAA

   
Results: 1-11 |
Results: 11
ANTISENSE TO ICAM-1 AFFECTS THE PERIPHERAL-BLOOD EXPRESSION AND INTESTINAL EXPRESSION OF ADHESION MOLECULES IN CROHNS-DISEASE
Authors: BOWENYACYSHYN MB SHANAHAN W BENNETT F TAMI J GALLATIN M ROTHLEIN B MAINOLFI E JEWELL L YACYSHYN BR
Citation: Mb. Bowenyacyshyn et al., ANTISENSE TO ICAM-1 AFFECTS THE PERIPHERAL-BLOOD EXPRESSION AND INTESTINAL EXPRESSION OF ADHESION MOLECULES IN CROHNS-DISEASE, Gastroenterology, 114(4), 1998, pp. 3851-3851
SAFETY OF RETREATMENT WITH ANTISENSE TO ICAM-1 (ISIS-2302) IN PATIENTS WITH STEROID-DEPENDENT CROHNS-DISEASE
Authors: YACYSHYN BR BOWENYACYSHYN MB TAMI J SAHBA B SHANAHAN W
Citation: Br. Yacyshyn et al., SAFETY OF RETREATMENT WITH ANTISENSE TO ICAM-1 (ISIS-2302) IN PATIENTS WITH STEROID-DEPENDENT CROHNS-DISEASE, Gastroenterology, 114(4), 1998, pp. 4574-4574
HUMAN IG HEAVY-CHAIN CDR3 REGIONS IN ADULT BONE-MARROW PRE-B CELLS DISPLAY AN ADULT PHENOTYPE OF DIVERSITY - EVIDENCE FOR STRUCTURAL SELECTION OF D-H AMINO-ACID-SEQUENCES
Authors: RAAPHORST FM RAMAN CS TAMI J FISCHBACH M SANZ I
Citation: Fm. Raaphorst et al., HUMAN IG HEAVY-CHAIN CDR3 REGIONS IN ADULT BONE-MARROW PRE-B CELLS DISPLAY AN ADULT PHENOTYPE OF DIVERSITY - EVIDENCE FOR STRUCTURAL SELECTION OF D-H AMINO-ACID-SEQUENCES, International immunology, 9(10), 1997, pp. 1503-1515
EFFICACY AND SAFETY OF ISIS-2302 (ICAM-I ANTISENSE OLIGONUCLEOTIDE) TREATMENT OF STEROID-DEPENDENT CROHNS-DISEASE
Authors: YACYSHYN B WOLOSCHUK B YACYSHYN MB MARTINI D DOAN K TAMI J BENNETT F KISNER D SHANAHAN W
Citation: B. Yacyshyn et al., EFFICACY AND SAFETY OF ISIS-2302 (ICAM-I ANTISENSE OLIGONUCLEOTIDE) TREATMENT OF STEROID-DEPENDENT CROHNS-DISEASE, Gastroenterology, 112(4), 1997, pp. 1123-1123
CLONING OF SIZE-SELECTED HUMAN-IMMUNOGLOBULIN HEAVY-CHAIN REARRANGEMENTS FROM 3RD COMPLEMENTARITY-DETERMINING REGION FINGERPRINT PROFILES
Authors: RAAPHORST FM TAMI J SANZ IE
Citation: Fm. Raaphorst et al., CLONING OF SIZE-SELECTED HUMAN-IMMUNOGLOBULIN HEAVY-CHAIN REARRANGEMENTS FROM 3RD COMPLEMENTARITY-DETERMINING REGION FINGERPRINT PROFILES, BioTechniques, 20(1), 1996, pp. 78
EVIDENCE AGAINST CHRONIC ANTIGEN-SPECIFIC T-LYMPHOCYTE ACTIVATION IN MYASTHENIA-GRAVIS
Authors: INFANTE AJ INFANTE PD JACKSON CE BAROHN RJ TAMI J ITURRIAGA E TALIB S KRAIG E CLARKIN KZ KROLICK KA
Citation: Aj. Infante et al., EVIDENCE AGAINST CHRONIC ANTIGEN-SPECIFIC T-LYMPHOCYTE ACTIVATION IN MYASTHENIA-GRAVIS, Journal of neuroscience research, 45(4), 1996, pp. 492-499
EVALUATION OF BIOTECHNOLOGY PRODUCTS
Authors: TAMI J EVENS RP
Citation: J. Tami et Rp. Evens, EVALUATION OF BIOTECHNOLOGY PRODUCTS, Pharmacotherapy, 16(4), 1996, pp. 527-536
ELEVATION OF SOLUBLE INTERLEUKIN-2 RECEPTORS IN THE SERUM OF MYASTHENIA-GRAVIS (MG) PATIENTS
Authors: TAMI J JACKSON CE BAROHN RJ MCINTYRE W KROLICK K
Citation: J. Tami et al., ELEVATION OF SOLUBLE INTERLEUKIN-2 RECEPTORS IN THE SERUM OF MYASTHENIA-GRAVIS (MG) PATIENTS, Neurology, 45(4), 1995, pp. 353-353
CRYOPRESERVED MATCHED RELATED DONOR MARROW ENGRAFTS PROMPTLY FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: CASTRO J BACHIER C BOLDT DH FREYTES C HARRIS K ROODMAN D SALZMAN D TAMI J MENEGHETTI C SHERIDANLEOS N LEMAISTRE CF
Citation: J. Castro et al., CRYOPRESERVED MATCHED RELATED DONOR MARROW ENGRAFTS PROMPTLY FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 84(10), 1994, pp. 10000093-10000093
CLINICAL REMISSION OF MYASTHENIA-GRAVIS (MG) IN A PATIENT (PT) AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION WITH CD34-CELLS (SC)(STEM)
Authors: SALZMAN D TAMI J JACKSON C CASTRO J BOLDT D FREYTES C BERENSON R LEMAISTRE CF
Citation: D. Salzman et al., CLINICAL REMISSION OF MYASTHENIA-GRAVIS (MG) IN A PATIENT (PT) AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION WITH CD34-CELLS (SC)(STEM), Blood, 84(10), 1994, pp. 10000206-10000206
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN RESISTANT OR RECURRENT LOW-GRADE LYMPHOMA
Authors: FREYTES CO BACHIER C SALZMAN D VUKELIA S CASTRO J BOLDT D ROODMAN GD CRAIG F HARRIS K TSAI T SHERIDANLEOS N HILSENBECK S TAMI J BURRELL L LEMAISTRE CF
Citation: Co. Freytes et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN RESISTANT OR RECURRENT LOW-GRADE LYMPHOMA, Blood, 84(10), 1994, pp. 10000709-10000709
Risultati: 1-11 |